ID   BHP2-7 Pazopanib selected
AC   CVCL_4W01
DR   Wikidata; Q54796506
RX   PubMed=24628546;
CC   Problematic cell line: Contaminated. Parent cell line (BHP 2-7) has been shown to be a TPC-1 derivative.
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_71219; Pazopanib (Votrient).
CC   Sequence variation: Gene fusion; HGNC; HGNC:18782; CCDC6 + HGNC; HGNC:9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Ala68fs (c.204_208delGGAGC); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11355; STAG2; Simple; p.Gln1089Ter (c.3265C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line).
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
DI   NCIt; C4035; Thyroid gland papillary carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6283 ! BHP 2-7
SX   Female
AG   Adult
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 19-12-24; Version: 15
//
RX   PubMed=24628546; DOI=10.1210/jc.2013-2658; PMCID=PMC5393484;
RA   Isham, Crescent R.
RA   Netzel, Brian C.
RA   Bossou, Ayoko R.
RA   Milosevic, Dragana
RA   Cradic, Kendall W.
RA   Grebe, Stefan K.G.
RA   Bible, Keith C.
RT   "Development and characterization of a differentiated thyroid cancer
RT   cell line resistant to VEGFR-targeted kinase inhibitors.";
RL   J. Clin. Endocrinol. Metab. 99:E936-E943(2014).
//